Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough Coricidin repositioning targets hypertension concerns with decongestants.

This article was originally published in The Tan Sheet

Executive Summary

CORICIDIN COUGH/COLD LINE REPOSITIONING TARGETS HYPERTENSION CONCERNS by highlighting the fact three of the products do not contain decongestant ingredients such as pseudoephedrine/ephedrine, phenylephrine and phenylpropanolamine that may cause problems for those with high blood pressure or interfere with medication for the condition. Schering-Plough has repackaged its Coricidin Cold & Flu Tablets, Cold & Cough Tablets and NightTime Cold & Cough Liquid and renamed the line Coricidin HBP. The products are expected to reach stores by the end of January.
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS087956

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel